Locations:
SearchDr. Mikkael Sekeres in his latest New York Times column
Patients with cancer, and especially those receiving treatment, are approaching their physicians with questions about their risk of contracting COVID-19. Mikkael Sekeres, MD, MS, Director of Cleveland Clinic Cancer Center’s Leukemia Program, offers an expert’s perspective on the existing research in his latest New York Timescolumn. His answer to the question of whether cancer and chemotherapy increase the risk of death from COVID-19 provides a comprehensive look at existing research in patient-friendly language that can be a useful tool in communicating with your patients.
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Read the column here.
Follow Dr. Sekeres on Twitter @MikkaelSekeres.
Advertisement
Advertisement
First-of-its-kind research investigates the viability of standard screening to reduce the burden of late-stage cancer diagnoses
Global R&D efforts expanding first-line and relapse therapy options for patients
Study demonstrates ability to reduce patients’ reliance on phlebotomies to stabilize hematocrit levels
A case study on the value of access to novel therapies through clinical trials
Findings highlight an association between obesity and an increased incidence of moderate-severe disease
Cleveland Clinic Cancer Institute takes multi-faceted approach to increasing clinical trial access 23456
Key learnings from DESTINY trials
Overall survival in patients treated since 2008 is nearly 20% higher than in earlier patients